All Type of News
2 of 3 listed pharmas are having under 10% operating profit ratio
While increases in introduced products and SG&A expenses have been criticized as the main causes to weaken the pharmaceutical companies’ profitability, it was observed there were only 21 pharmaceutical companies excee...
Which pharmas have high chance to fight against big pharmas in global market?
Pharmaceutical companies have drawn a big picture for the competition against global pharmaceutical companies in the leading markets, but the competition has not started yet.
The place where the pharmaceutical compan...
Chronic kidney patients with abdominal obesity have double chance of getting cardiovascular disease
In order to celebrate the World Kidney Day on the 9th, the Korea Centers for Disease Control and Prevention(Director Jung-Ki Suck) announced a research report that abdominal obesity patients have the highest chance of...
National Assembly’s debate for adjustment of household drugs at convenient stores
While the government has created an issue as trying to adjust the number of emergency household products, it will conduct debates related to it.
The National Assembly Health and Welfare Committee’s Rep. Do-Ja Choi(Pe...
‘Expense Report for Economic Benefits’ confirmed to include signatures, but exclude license number
A form for the ‘Expense Report for Economic Benefits,’ which will play a key role in exposing illegal rebates, was practically confirmed. The medical and pharmaceutical fields agreed over excluding license numbers of ...
Pharmas will shoot global new drugs within 2-3 years with devotion to pipelines
As Korean pharmaceutical companies’ pipelines led to new drugs, it seems the era that they compete against multinational pharmaceutical companies will raise. Korean pharmaceutical companies’ CEOs have raised an expect...
Listed pharmaceutical companies weakened in profitability while recording similar amount of sales with the average year
Although listed pharmaceutical companies recorded a growth rate that is approximate to 7%, it was analyzed they were weakened in profitability.
According to the Yakup Shinmoon’s analysis result of 57 KOSPI and KOSDAQ...
MSD Korea appoints Jae-Yeon Choi as Head-Overseas Cooperation
MSD Korea announced appointment of Ms. Jae-Yeon Choi, a new executive director, as Head-Overseas Cooperation from the 8th of March.
After joining in the multinational pharmaceutical company Lilly Korea in 2004, Jae-Y...
KPDS, “Conditionally-approved Tasigna’s clinical trial result must be disclosed”
Korean Pharmacists for Democratic Society(KPDS) announced to make a request for disclosure of the clinical trial result of Novartis’ ‘Tasigna.’
Novartis acquired conditional approval for the Phase 3 clinical trial of...
Yuhan Corporation generates 21 blockbuster drugs recording over KRW 10 billion sales
It was observed Yuhan Corporation made KRW 140 billion sales with the hepatitis B treatment ‘Viread’ last year.
Moreover, the company was recorded to spend 6.5% of sales, KRW 85.2 billion, into R&D.
With Viread whic...
